Mesterolone 25mg/tab 50 Tabletten by Hilma Biocare

Usage

1. Confirm cycle history and degree of suppression via baseline bloodwork — total testosterone, LH, FSH, and SHBG — taken at least 2–3 half-lives after the last long-ester AAS injection.
2. If testicular atrophy is pronounced after a heavy multi-compound run, complete a 2–4-week HCG priming phase before introducing mesterolone or any SERM.
3. On the first day of the concurrent SERM-plus-mesterolone phase, take two Hilma Biocare Mesterolone 25mg tablets (50 mg total) in the morning with food to reduce potential gastric discomfort.
4. Continue the 50 mg daily mesterolone dose throughout the SERM phase — typically 8–10 weeks for heavy-cycle recovery — without cycling off between weeks.
5. On SERM discontinuation, reduce mesterolone to one tablet (25 mg) daily for a 2–4-week taper, then reassess serum testosterone before full cessation.
6. Obtain repeat bloodwork — total testosterone, free testosterone, LH, FSH — at the end of the taper to verify HPTA consolidation; consult a physician if values remain below the lower reference limit.

Warnings

Frequently asked questions

What makes PCT after a heavy or long-duration AAS cycle fundamentally different from standard post-cycle recovery?

Heavy-cycle PCT is more demanding because prolonged or high-dose AAS use causes deeper HPG-axis suppression, greater testicular atrophy, and elevated SHBG levels that reduce the biological impact of recovered endogenous testosterone. Recovery timelines extend to 12–20 weeks in some cases, and a preliminary HCG phase — absent in mild-cycle protocols — is often necessary before SERMs and androgenic support like mesterolone are introduced.

When should HCG be used before starting mesterolone and a SERM in a heavy-cycle PCT?

HCG is typically introduced first when testicular atrophy is significant after a long cycle — usually 500–2500 IU every other day for 2–4 weeks. This primes Leydig cells and partially restores testicular volume before gonadotropin-stimulating SERMs and peripheral androgen support from mesterolone are layered in. Starting mesterolone alongside HCG without a SERM is a recognised transitional approach.

How long does HPTA recovery realistically take after a 16-plus-week multi-compound AAS cycle?

Clinical endocrinology data and anecdotal monitoring both suggest HPTA recovery after prolonged heavy cycles can take 6–18 months to full baseline testosterone restoration, with 90-day serum testosterone checks (total and LH/FSH) used to track progress. Structured PCT — including mesterolone for SHBG displacement and a SERM for gonadotropin stimulation — compresses the symptomatic recovery window significantly compared to unassisted recovery.

How does the 25 mg per-tablet strength of Hilma Biocare Mesterolone simplify dosing during a long PCT protocol?

At 25 mg per tablet, the Hilma Biocare format matches the standard clinical unit dose; a 50 mg daily dose requires exactly two tablets, and a 75 mg dose (occasionally used in the first four weeks of heavy-cycle PCT) requires three — all without splitting. This 25 mg strength is the highest standard tablet concentration in the mesterolone category, avoiding the need for dose stacking with lower-strength tabs.

Does the 50-tablet pack provide sufficient supply for the full androgenic support phase of a heavy-cycle PCT?

A 50-tablet pack covers 8 weeks at 25 mg daily or 4 weeks at 50 mg daily — adequate for a single phase of a heavy-cycle protocol. Most heavy-cycle PCT practitioners source two packs to cover the full 8–10-week concurrent SERM phase at 50 mg plus a subsequent 2–4-week taper at 25 mg, maintaining uninterrupted androgenic support across the entire recovery arc. (2) angle_used

Manufacturer

Hilma Biocare's tablet presentation for Mesterolone 25mg/tab is organised around a compound-exclusive release record rather than a shared portfolio certificate: raw mesterolone API undergoes HPLC identity and quantitative potency analysis against a certified reference compound at the point of intake, that data is assigned to a batch-specific dossier unique to this SKU, and the same analytical instrument re-examines finished tablets after GMP-certified compression to produce an instrument-derived per-tablet content figure — not a theoretical calculation. The 50-tablet sealed pack is authorised for release only when all parameters in that batch record, including tablet-weight uniformity data captured during in-process controls, satisfy the compound-level acceptance criteria. For the extended, high-stakes recovery demands of heavy-cycle PCT — where dosing consistency across 10–16 weeks is non-negotiable — this per-batch, per-compound documentation architecture provides traceability that a shared-lot system cannot replicate.